Allele-specific silencing of mutant huntingtin and ataxin-3 genes by targeting expanded CAG repeats in mRNAs

[1]  R. Friedlander,et al.  Allele‐specific silencing of mutant Huntington’s disease gene , 2009, Journal of neurochemistry.

[2]  D. Sah,et al.  Novel Therapeutic Modalities to Address Nondrugable Protein Interaction Targets , 2009, Neuropsychopharmacology.

[3]  N. Déglon,et al.  Allele-Specific RNA Silencing of Mutant Ataxin-3 Mediates Neuroprotection in a Rat Model of Machado-Joseph Disease , 2008, PloS one.

[4]  E. Burright,et al.  Identification and allele-specific silencing of the mutant huntingtin allele in Huntington's disease patient-derived fibroblasts. , 2008, Human gene therapy.

[5]  S. Kauppinen,et al.  Chapter 5:Locked Nucleic Acid: Properties and Therapeutic Aspects , 2008 .

[6]  K. G. Rajeev,et al.  Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits , 2007, Proceedings of the National Academy of Sciences.

[7]  Ralph Weissleder,et al.  MicroRNA-21 knockdown disrupts glioma growth in vivo and displays synergistic cytotoxicity with neural precursor cell delivered S-TRAIL in human gliomas. , 2007, Cancer research.

[8]  H. Zoghbi,et al.  Trinucleotide repeat disorders. , 2007, Annual review of neuroscience.

[9]  D. Corey,et al.  Inhibiting gene expression with peptide nucleic acid (PNA)--peptide conjugates that target chromosomal DNA. , 2007, Biochemistry.

[10]  H. Paulson,et al.  Dominantly Inherited Ataxias: Lessons Learned from Machado-Joseph Disease/Spinocerebellar Ataxia Type 3 , 2007, Seminars in neurology.

[11]  David R Corey,et al.  RNA learns from antisense. , 2007, Nature chemical biology.

[12]  M. Manoharan,et al.  RNAi therapeutics: a potential new class of pharmaceutical drugs , 2006, Nature chemical biology.

[13]  M. MacDonald,et al.  Huntington's disease: seeing the pathogenic process through a genetic lens. , 2006, Trends in biochemical sciences.

[14]  B. Monia,et al.  Antisense oligonucleotide therapy for neurodegenerative disease. , 2006, The Journal of clinical investigation.

[15]  J. Schelter,et al.  Designing siRNA That Distinguish between Genes That Differ by a Single Nucleotide , 2006, PLoS genetics.

[16]  H. Paulson,et al.  Allele-specific RNA interference for neurological disease , 2006, Gene Therapy.

[17]  B. Davidson,et al.  RNAi: a potential therapy for the dominantly inherited nucleotide repeat diseases , 2006, Gene Therapy.

[18]  I. Kanazawa,et al.  Clinico-pathological rescue of a model mouse of Huntington's disease by siRNA , 2005, Neuroscience Research.

[19]  D. Corey,et al.  Inhibiting transcription of chromosomal DNA with antigene peptide nucleic acids , 2005, Nature chemical biology.

[20]  B. Armitage,et al.  RNA guanine quadruplex invasion by complementary and homologous PNA probes. , 2005, Journal of the American Chemical Society.

[21]  H. Paulson,et al.  RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[22]  R. Llinás,et al.  Disturbed Ca2+ signaling and apoptosis of medium spiny neurons in Huntington's disease. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[23]  Jacek Krol,et al.  RNA structure of trinucleotide repeats associated with human neurological diseases. , 2003, Nucleic acids research.

[24]  E. Simpson,et al.  Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. , 2003, Human molecular genetics.

[25]  Haibin Xia,et al.  Allele-specific silencing of dominant disease genes , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[26]  V. Erdmann,et al.  Design of antisense oligonucleotides stabilized by locked nucleic acids. , 2002, Nucleic acids research.

[27]  L. Thompson,et al.  Antisense-mediated down-regulation of the human huntingtin gene. , 2000, The Journal of pharmacology and experimental therapeutics.

[28]  T. Hökfelt,et al.  Potent and nontoxic antisense oligonucleotides containing locked nucleic acids. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[29]  Jacqueline K. White,et al.  Huntingtin is required for neurogenesis and is not impaired by the Huntington's disease CAG expansion , 1997, Nature Genetics.

[30]  P. Nielsen,et al.  Antisense properties of duplex- and triplex-forming PNAs. , 1996, Nucleic acids research.

[31]  D. Corey.  48000-FOLD ACCELERATION OF HYBRIDIZATION BY CHEMICALLY MODIFIED OLIGONUCLEOTIDES , 1995 .

[32]  S. Floresco,et al.  Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes , 1995, Cell.

[33]  G. Sobue,et al.  Molecular features of the CAG repeats and clinical manifestation of Machado-Joseph disease. , 1995, Human molecular genetics.

[34]  Paul W Goldberg,et al.  A worldwide study of the Huntington's disease mutation. The sensitivity and specificity of measuring CAG repeats. , 1994, The New England journal of medicine.

[35]  Joseph B. Martin.  Huntington's disease , 1984, Neurology.